Steward Partners Investment Advisory LLC trimmed its stake in shares of Chemed Co. (NYSE:CHE – Get Rating) by 86.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 295 shares of the company’s stock after selling 1,880 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Chemed were worth $149,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC increased its position in Chemed by 5.2% in the 4th quarter. Kayne Anderson Rudnick Investment Management LLC now owns 487,074 shares of the company’s stock valued at $257,682,000 after acquiring an additional 23,949 shares during the period. William Blair Investment Management LLC increased its position in Chemed by 22.5% in the 4th quarter. William Blair Investment Management LLC now owns 418,761 shares of the company’s stock valued at $221,541,000 after acquiring an additional 76,904 shares during the period. JPMorgan Chase & Co. increased its position in Chemed by 1.7% in the 4th quarter. JPMorgan Chase & Co. now owns 314,913 shares of the company’s stock valued at $166,602,000 after acquiring an additional 5,247 shares during the period. Boston Trust Walden Corp increased its position in Chemed by 7.5% in the 1st quarter. Boston Trust Walden Corp now owns 240,028 shares of the company’s stock valued at $121,586,000 after acquiring an additional 16,809 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in Chemed by 4.1% in the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 169,574 shares of the company’s stock valued at $89,711,000 after acquiring an additional 6,670 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, Royal Bank of Canada lowered their target price on Chemed from $592.00 to $541.00 in a research report on Monday.
Chemed Stock Down 2.2 %
Chemed (NYSE:CHE – Get Rating) last issued its quarterly earnings results on Wednesday, July 27th. The company reported $4.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.06. Chemed had a return on equity of 44.64% and a net margin of 12.95%. The company had revenue of $531.29 million for the quarter, compared to analysts’ expectations of $538.07 million. During the same period last year, the firm earned $4.60 EPS. The firm’s revenue for the quarter was down .2% on a year-over-year basis. Equities analysts expect that Chemed Co. will post 18.98 earnings per share for the current fiscal year.
Chemed Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Wednesday, June 15th. Stockholders of record on Thursday, May 26th were given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend was Wednesday, May 25th. Chemed’s dividend payout ratio (DPR) is presently 8.01%.
Insider Activity
In other news, CFO David Patrick Williams sold 4,000 shares of the firm’s stock in a transaction on Friday, May 6th. The stock was sold at an average price of $500.38, for a total transaction of $2,001,520.00. Following the completion of the sale, the chief financial officer now directly owns 30,856 shares of the company’s stock, valued at approximately $15,439,725.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CFO David Patrick Williams sold 4,000 shares of the firm’s stock in a transaction on Friday, May 6th. The stock was sold at an average price of $500.38, for a total transaction of $2,001,520.00. Following the completion of the sale, the chief financial officer now directly owns 30,856 shares of the company’s stock, valued at approximately $15,439,725.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $502.00, for a total value of $1,004,000.00. Following the sale, the chief executive officer now directly owns 128,185 shares of the company’s stock, valued at $64,348,870. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,694 shares of company stock worth $3,843,616. 4.03% of the stock is owned by company insiders.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Featured Stories
- Get a free copy of the StockNews.com research report on Chemed (CHE)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook BrightensÂ
- Deep Value High Yield Newell Brands Is Ready To BottomÂ
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.